Joong Sup Shim

List of Publications by Year
in descending order

69 papers	4,897 citations	136740 32 h-index	95083 68 g-index
72 all docs	72 docs citations	72 times ranked	9239 citing authors

#	Article	IF	Citations
1	Genetic and pharmacological disruption of the TEADâ€“YAP complex suppresses the oncogenic activity of YAP. Genes and Development, 2012, 26, 1300-1305.	2.7	1,135
2	Targeting Epithelialâ€“Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 2016, 21, 965.	1.7	548
3	Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs. International Journal of Biological Sciences, 2014, 10, 654-663.	2.6	293
4	Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology, 2013, 57, 2458-2468.	3.6	216
5	Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate, 2011, 71, 333-343.	1.2	158
6	Irreversible Inhibition of CD13/Aminopeptidase N by the Antiangiogenic Agent Curcumin. Chemistry and Biology, 2003, 10, 695-704.	6.2	156
7	A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. Cancer Discovery, 2011, 1, 68-77.	7.7	145
8	Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB of Mitochondrial Complex III and Suppressing Hypoxia-induced Reactive Oxygen Species Production and Cellular Oxygen Sensing. Journal of Biological Chemistry, 2010, 285, 11584-11595.	1.6	101
9	A New Curcumin Derivative, HBC, Interferes with the Cell Cycle Progression of Colon Cancer Cells via Antagonization of the Ca2+/Calmodulin Function. Chemistry and Biology, 2004, 11, 1455-1463.	6.2	100
10	Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nature Communications, 2018, 9, 3212.	5.8	97
11	Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer. Journal of the National Cancer Institute, 2010, 102, 1855-1873.	3.0	95
12	First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic Î²-cell mass. ELife, 2015, 4, .	2.8	89
13	Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E7276-85.	3.3	84
14	Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Experimental and Molecular Medicine, 2005, 37, 133-137.	3.2	81
15	Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19264-19269.	3.3	80
16	Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. Journal of the National Cancer Institute, 2012, 104, 1576-1590.	3.0	76
17	Betulinic Acid Inhibits Growth Factor-induced in vitro Angiogenesis via the Modulation of Mitochondrial Function in Endothelial Cells. Japanese Journal of Cancer Research, 2002, 93, 417-425.	1.7	74
18	Anti-Angiogenic Activity of a Homoisoflavanone fromcremastra appendiculata. Planta Medica, 2004, 70, 171-173.	0.7	72

#	Article	IF	Citations
19	Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorganic and Medicinal Chemistry, 2002, 10, 2987-2992.	1.4	69
20	Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Letters, 2004, 203, 163-169.	3.2	68
21	Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. ACS Chemical Biology, 2017, 12, 174-182.	1.6	66
22	Microarray-based Analysis of Anti-angiogenic Activity of Demethoxycurcumin on Human Umbilical Vein Endothelial Cells: Crucial Involvement of the Down-regulation of Matrix Metalloproteinase. Japanese Journal of Cancer Research, 2002, 93, 1378-1385.	1.7	65
23	Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Letters, 2017, 409, 91-103.	3.2	50
24	Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications, 2021, 12, 3046.	5.8	48
25	Aurora kinase A, a synthetic lethal target for precision cancer medicine. Experimental and Molecular Medicine, 2021, 53, 835-847.	3.2	46
26	Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochemical and Biophysical Research Communications, 2007, 359, 523-528.	1.0	44
27	Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochemical and Biophysical Research Communications, 2007, 363, 336-341.	1.0	43
28	Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 782-786.	1.3	43
29	Hydrazinocurcumin, a novel synthetic curcumin derivative, Is a potent inhibitor of endothelial cell proliferation. Bioorganic and Medicinal Chemistry, 2002, 10, 2439-2444.	1.4	42
30	Cholesterol Trafficking: An Emerging Therapeutic Target for Angiogenesis and Cancer. Cells, 2019, 8, 389.	1.8	41
31	Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy, 2021, 17, 2783-2799.	4.3	40
32	Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics. Nature Communications, 2020, 11, 5105.	5.8	36
33	A Novel Ca2+/Calmodulin Antagonist HBC Inhibits Angiogenesis and Down-regulates Hypoxia-inducible Factor. Journal of Biological Chemistry, 2010, 285, 25867-25874.	1.6	34
34	Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Organic and Biomolecular Chemistry, 2012, 10, 2979.	1.5	29
35	Antidepressant indatraline induces autophagy and inhibits restenosis via suppression of mTOR/S6 kinase signaling pathway. Scientific Reports, 2016, 6, 34655.	1.6	29
36	Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. British Journal of Pharmacology, 2014, 171, 4478-4489.	2.7	27

#	Article	IF	Citations
37	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. Clinical Cancer Research, 2013, 19, 1139-1146.	3.2	24
38	Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharmaceutica Sinica B, 2020, 10, 615-627.	5.7	24
39	Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Letters, 2015, 362, 106-115.	3.2	23
40	Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene, 2004, 23, 1704-1711.	2.6	22
41	Astemizole Inhibits mTOR Signaling and Angiogenesis by Blocking Cholesterol Trafficking. International Journal of Biological Sciences, 2018, 14, 1175-1185.	2.6	22
42	Existing drugs and their application in drug discovery targeting cancer stem cells. Archives of Pharmacal Research, 2015, 38, 1617-1626.	2.7	21
43	Modified Oligonucleotides Containing Lithocholic Acid in Their Backbones: Their Enhanced Cellular Uptake and Their Mimicking of Hairpin Structures. ChemBioChem, 2004, 5, 1517-1522.	1.3	20
44	Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncology Reports, 2014, 32, 419-424.	1.2	19
45	N-Hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 181-183.	1.0	18
46	Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochemical and Biophysical Research Communications, 2007, 359, 747-751.	1.0	18
47	Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Science, 2007, 98, 1943-1948.	1.7	17
48	Purpurin inhibits adipocyte-derived leucine aminopeptidase and angiogenesis in a zebrafish model. Biochemical and Biophysical Research Communications, 2014, 450, 561-567.	1.0	17
49	Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT. International Journal of Biological Sciences, 2020, 16, 1774-1784.	2.6	17
50	Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1 in Cells. Journal of Medicinal Chemistry, 2013, 56, 3996-4016.	2.9	16
51	Ring Expansion Leads to a More Potent Analogue of Ipomoeassin F. Journal of Organic Chemistry, 2020, 85, 16226-16235.	1.7	16
52	Chemical genetics for therapeutic target mining. Expert Opinion on Therapeutic Targets, 2004, 8, 653-661.	1.5	15
53	Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression. Oncogene, 2021, 40, 937-950.	2.6	15
54	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 2021, 10, .	2.8	15

#	Article	IF	Citations
55	The Small Molecule R-(-)-Î²-O-Methylsynephrine Binds to Nucleoporin 153 kDa and Inhibits Angiogenesis. International Journal of Biological Sciences, 2015, 11, 1088-1099.	2.6	14
56	BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition. Oncogene, 2018, 37, 6341-6356.	2.6	14
57	Tricyclic thiazoles are a new class of angiogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2733-2737.	1.0	13
58	Revisiting Non-Cancer Drugs for Cancer Therapy. Current Topics in Medicinal Chemistry, 2016, 16, 2144-2155.	1.0	13
59	Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole. Clinical Cancer Research, 2016, 22, 2709-2720.	3.2	12
60	Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells. Cancer Biology and Therapy, 2013, 14, 401-410.	1.5	10
61	PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Letters, 2018, 436, 28-37.	3.2	10
62	Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. Biochemical and Biophysical Research Communications, 2007, 353, 376-380.	1.0	8
63	Identification and validation of calmodulin as a binding protein of an antiâ€proliferative small molecule 3,4â€dihydroisoquinolinium salt. Proteomics - Clinical Applications, 2009, 3, 423-432.	0.8	8
64	Cell Cycle Inhibitory Activity of 4-Hydroxy-3-(3'-methyl-2'-butenyl)-benzoic Acid from Curvularia sp. KF119. Journal of Antibiotics, 2004, 57, 605-608.	1.0	7
65	Natural products targeting cancer cell dependency. Journal of Antibiotics, 2021, 74, 677-686.	1.0	7
66	Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation. Oncogene, 2022, 41, 2734-2748.	2.6	6
67	Coordinated transcriptional regulation of calmegin, a testis-specific molecular chaperon, by histone deacetylase and CpG methyltransferase. Experimental and Molecular Medicine, 2005, 37, 492-496.	3.2	5
68	Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. Biochemical and Biophysical Research Communications, 2008, 371, 99-103.	1.0	5
69	Development of an angiogenesis-focused cDNA chip and validation of its functionality. Experimental and Molecular Medicine, 2005, 37, 365-370.	3.2	4